Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00134-020-06141-z http://scihub22266oqcxt.onion/10.1007/s00134-020-06141-z 32654006!7352097!32654006     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Intensive+Care+Med 2020 ; 46 (12): 2265-2283 Nephropedia Template TP {{tp|p=32654006|t=2020. Emerging pharmacological therapies for ARDS: COVID-19 and beyond |pdf=|usr=}}{{32654006}} gab.com Text Emerging pharmacological therapies for ARDS: COVID-19 and beyond JO: Intensive Care Med http://www.kidney.de/pget.php?&tw=1&pmid=32654006 #FOAvip ARDS, first described in 1967, is the commonest form of acute severe hypoxemic respiratory failure. Despite considerable advances in our knowledge regarding the pathophysiology of ARDS, insights into the biologic mechanisms of lung injury and repair, and advances in supportive care, particularly ventilatory management, there remains no effective pharmacological therapy for this syndrome. Hospital mortality at 40% remains unacceptably high underlining the need to continue to develop and test therapies for this devastating clinical condition. The purpose of the review is to critically appraise the current status of promising emerging pharmacological therapies for patients with ARDS and potential impact of these and other emerging therapies for COVID-19-induced ARDS. We focus on drugs that: (1) modulate the immune response, both via pleiotropic mechanisms and via specific pathway blockade effects, (2) modify epithelial and channel function, (3) target endothelial and vascular dysfunction, (4) have anticoagulant effects, and (5) enhance ARDS resolution. We also critically assess drugs that demonstrate potential in emerging reports from clinical studies in patients with COVID-19-induced ARDS. Several therapies show promise in earlier and later phase clinical testing, while a growing pipeline of therapies is in preclinical testing. The history of unsuccessful clinical trials of promising therapies underlines the challenges to successful translation. Given this, attention has been focused on the potential to identify biologically homogenous subtypes within ARDS, to enable us to target more specific therapies 'precision medicines.' It is hoped that the substantial number of studies globally investigating potential therapies for COVID-19 will lead to the rapid identification of effective therapies to reduce the mortality and morbidity of this devastating form of ARDS. Twit Text FOAVip Emerging pharmacological therapies for ARDS: COVID-19 and beyond ????Intensive Care Med http://www.kidney.de/pget.php?&tw=1&pmid=32654006 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32654006 #FOAvip English Wikipedia <ref>{{Cite pmid|32654006}}</ref> Emerging pharmacological therapies for ARDS: COVID-19 and beyond #MMPMID32654006 Horie S; McNicholas B; Rezoagli E; Pham T; Curley G; McAuley D; O'Kane C; Nichol A; Dos Santos C; Rocco PRM; Bellani G; Laffey JG Intensive Care Med 2020[Dec]; 46 (12): 2265-2283 PMID32654006show ga ARDS, first described in 1967, is the commonest form of acute severe hypoxemic respiratory failure. Despite considerable advances in our knowledge regarding the pathophysiology of ARDS, insights into the biologic mechanisms of lung injury and repair, and advances in supportive care, particularly ventilatory management, there remains no effective pharmacological therapy for this syndrome. Hospital mortality at 40% remains unacceptably high underlining the need to continue to develop and test therapies for this devastating clinical condition. The purpose of the review is to critically appraise the current status of promising emerging pharmacological therapies for patients with ARDS and potential impact of these and other emerging therapies for COVID-19-induced ARDS. We focus on drugs that: (1) modulate the immune response, both via pleiotropic mechanisms and via specific pathway blockade effects, (2) modify epithelial and channel function, (3) target endothelial and vascular dysfunction, (4) have anticoagulant effects, and (5) enhance ARDS resolution. We also critically assess drugs that demonstrate potential in emerging reports from clinical studies in patients with COVID-19-induced ARDS. Several therapies show promise in earlier and later phase clinical testing, while a growing pipeline of therapies is in preclinical testing. The history of unsuccessful clinical trials of promising therapies underlines the challenges to successful translation. Given this, attention has been focused on the potential to identify biologically homogenous subtypes within ARDS, to enable us to target more specific therapies 'precision medicines.' It is hoped that the substantial number of studies globally investigating potential therapies for COVID-19 will lead to the rapid identification of effective therapies to reduce the mortality and morbidity of this devastating form of ARDS. |*COVID-19 Drug Treatment[MESH] |Antioxidants/therapeutic use[MESH] |Ascorbic Acid/therapeutic use[MESH] |Citrulline/therapeutic use[MESH] |Drug Therapy/*trends[MESH] |Glycoproteins/therapeutic use[MESH] |Humans[MESH] |Mesenchymal Stem Cells[MESH] |Pandemics[MESH] |Peptides, Cyclic/therapeutic use[MESH] |Pyridones/therapeutic use[MESH] |Pyrimidines/therapeutic use[MESH] |Receptors, Tumor Necrosis Factor, Type I/antagonists & inhibitors/therapeutic use[MESH] |Respiratory Distress Syndrome/*drug therapy[MESH] |Steroids/therapeutic use[MESH]Emerging pharmacological therapies for ARDS: COVID-19 and beyond (epmc).pdf DeepDyve Pubget Overpricing